HBW-3210

HBW-3210 is a third-generation, orally active, reversible Bruton's tyrosine kinase (BTK) inhibitor developed by Chengdu Hyperway Pharmaceuticals. It is designed to overcome resistance caused by the BTK C481S mutation and demonstrates high brain permeability (brain penetration rate >60% in preclinical models), making it particularly promising for central nervous system (CNS) B-cell malignancies. Preclinical and early clinical data indicate that HBW-3210 has potent antitumor activity against various B-cell lymphomas—including primary central nervous system lymphoma (PCNSL), secondary CNS lymphoma (SCNSL), chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, and diffuse large B-cell lymphoma—and can induce tumor shrinkage even in patients previously treated with irreversible BTK inhibitors. The drug has shown a favorable safety profile with no dose-limiting toxicities reported to date[1][2][3][6].